Klacid (Clarithromycin)

Clarithromycin exerts its antibacterial effect by binding to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis. This inhibition halts peptide chain elongation, resulting in a bacteriostatic effect at usual concentrations and a bactericidal effect when drug levels are high or the host immune response is robust.

The dosage of Klacid is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and local antimicrobial guidelines. Healthcare professionals select the appropriate infusion rate and duration, and the regimen may be adjusted during therapy as needed.

Clarithromycin is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy when the potential benefit justifies any potential risk. Use while breastfeeding should be considered only if the infant’s need for treatment outweighs possible exposure through milk.

To place an order, submit an enquiry on the Klacid product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Klacid (clarithromycin) shares the macrolide class mechanism with azithromycin and erythromycin but offers a broader spectrum against certain Gram‑positive and atypical organisms and higher tissue penetration. It is available as an intravenous formulation, which can be advantageous for patients unable to take oral medication, whereas azithromycin is typically given orally or intravenously in different dosing schedules.

Klacid should be stored at controlled room temperature, below 25 °C (77 °F). Keep the vials in their original packaging, protect them from moisture and direct light, and do not freeze. Once reconstituted, use the solution within the time frame specified in the product labeling and discard any remaining material.

Klacid is supplied as a sterile intravenous solution for infusion. The medication is diluted in an appropriate compatible fluid and administered through a peripheral or central venous line over the infusion period recommended by the prescribing clinician, typically ranging from 30 minutes to several hours depending on the infection being treated.

The most serious adverse reactions to Klacid include severe allergic responses such as anaphylaxis, cardiac arrhythmias related to QT‑interval prolongation, hepatotoxicity, Clostridioides difficile‑associated colitis, and rare dermatologic events like Stevens‑Johnson syndrome. Patients should be monitored for these signs, especially if they have pre‑existing cardiac disease or liver impairment.

Klacid is contraindicated in individuals with a known hypersensitivity to clarithromycin, other macrolide antibiotics, or any component of the formulation. It should also be avoided in patients taking drugs that can cause serious cardiac rhythm disturbances when combined with clarithromycin, unless a risk‑benefit assessment justifies use under close monitoring.